EUROVACC FOUNDATION

Their core work

EUROVACC Foundation is a Swiss-based non-profit dedicated to accelerating vaccine development, particularly for HIV, influenza, and emerging infectious diseases like COVID-19. They contribute immunological expertise, clinical trial design, and immune monitoring capabilities to large European vaccine consortia. Their work spans the full translational pipeline — from preclinical validation through human challenge trials — serving as a specialized partner that bridges laboratory immunology with clinical evaluation.

What they specialise in

How they've shifted over time

EUROVACC began its H2020 involvement with a deep focus on HIV vaccine research, contributing immunological and virological platform expertise through the EHVA alliance starting in 2016. By 2020, they pivoted sharply toward broader infectious disease challenges — joining both the COVID-19 emergency response (CARE) and a next-generation influenza vaccine consortium (INCENTIVE). This shift shows a foundation that expanded from a single-pathogen focus to a multi-disease vaccine platform, adding health economics, technology transfer, and pandemic preparedness to their repertoire.

EUROVACC is evolving from an HIV-specific foundation toward a broader infectious disease vaccine platform with growing emphasis on pandemic preparedness and technology transfer.

How they like to work

EUROVACC operates exclusively as a consortium participant, never as coordinator — consistent with their role as a specialized foundation contributing domain expertise rather than managing large projects. With 101 unique partners across 21 countries from just 3 projects, they embed themselves in very large, multinational consortia. This makes them an accessible partner: they are experienced in navigating complex multi-partner structures and bring a focused contribution without competing for leadership.

Despite only 3 projects, EUROVACC has worked with 101 distinct partners across 21 countries, reflecting their participation in major European vaccine consortia. Their network spans broadly across the EU and beyond, including Indo-European collaboration through INCENTIVE.

What sets them apart

EUROVACC occupies a rare niche as a non-profit foundation specifically structured to support vaccine development across multiple disease areas. Unlike university labs focused on basic research or pharma companies driven by commercial pipelines, they sit in between — facilitating translational vaccine work from preclinical through human trials. Their Swiss base, combined with deep EU consortium experience and recent expansion to Indo-European partnerships, makes them a trusted neutral partner for international vaccine initiatives.

Highlights from their portfolio

• EHVA
  Major EU-wide HIV vaccine alliance running 7 years (2016-2023), one of the flagship European efforts to develop prophylactic and therapeutic HIV vaccines.
• INCENTIVE
  Indo-European consortium for next-generation influenza vaccines, notable for its global reach and focus on human challenge trials and vulnerable populations.
• CARE
  Emergency pandemic response project launched in 2020, demonstrating EUROVACC's ability to rapidly mobilize for new infectious disease threats.